Vibration of effects from diverse inclusion/exclusion criteria and analytical choices: 9216 different ways to perform an indirect comparison meta-analysis

被引:39
作者
Palpacuer, Clement [1 ,2 ]
Hammas, Karima [3 ,4 ]
Duprez, Renan [5 ]
Laviolle, Bruno [1 ,6 ,7 ]
Ioannidis, John P. A. [8 ,9 ,10 ,11 ,12 ]
Naudet, Florian [1 ,6 ,7 ,8 ]
机构
[1] Hop Pontchaillou, Ctr Invest Clin, INSERM 1414, 2 Rue Henri Guilloux, F-35033 Rennes 9, France
[2] Ctr Rene Gauducheau, Inst Cancerol lOuest, St Herblain, France
[3] Hop Bichat Claude Bernard, AP HP, Dept Epidemiol & Biostat & Clin Res, Paris, France
[4] Hop Bichat Claude Bernard, CIC EC 1425, INSERM, Paris, France
[5] Ctr Hosp Dinan St Brieuc, Fondat St Jean de Dieu, Dinan, France
[6] Rennes Univ Hosp, Dept Biol & Clin Pharmacol & Pharmacovigilance, Rennes, France
[7] Rennes 1 Univ, Lab Expt & Clin Pharmacol, Rennes, France
[8] Stanford Univ, Meta Res Innovat Ctr Stanford METRICS, Stanford, CA 94305 USA
[9] Stanford Univ, Dept Med, Stanford, CA 94305 USA
[10] Stanford Univ, Dept Hlth Res & Policy, Stanford, CA 94305 USA
[11] Stanford Univ, Dept Biomed Data Sci, Stanford, CA 94305 USA
[12] Stanford Univ, Dept Stat, Stanford, CA 94305 USA
关键词
Meta-analysis; Vibration of effect; Alcoholism; Nalmefene; Naltrexone; PLACEBO-CONTROLLED TRIAL; RANDOMIZED CLINICAL-TRIAL; COGNITIVE-BEHAVIORAL THERAPY; EXTENDED-RELEASE NALTREXONE; ALCOHOL-DEPENDENCE; DOUBLE-BLIND; NETWORK METAANALYSES; TARGETED NALTREXONE; COOCCURRING COCAINE; SYSTEMATIC REVIEWS;
D O I
10.1186/s12916-019-1409-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Different methodological choices such as inclusion/exclusion criteria and analytical models can yield different results and inferences when meta-analyses are performed. We explored the range of such differences, using several methodological choices for indirect comparison meta-analyses to compare nalmefene and naltrexone in the reduction of alcohol consumption as a case study. Methods All double-blind randomized controlled trials (RCTs) comparing nalmefene to naltrexone or one of these compounds to a placebo in the treatment of alcohol dependence or alcohol use disorders were considered. Two reviewers searched for published and unpublished studies in MEDLINE (August 2017), the Cochrane Library, Embase, and ClinicalTrials.gov and contacted pharmaceutical companies, the European Medicines Agency, and the Food and Drug Administration. The indirect comparison meta-analyses were performed according to different inclusion/exclusion criteria (based on medical condition, abstinence of patients before inclusion, gender, somatic and psychiatric comorbidity, psychological support, treatment administered and dose, treatment duration, outcome reported, publication status, and risk of bias) and different analytical models (fixed and random effects). The primary outcome was the vibration of effects (VoE), i.e. the range of different results of the indirect comparison between nalmefene and naltrexone. The presence of a "Janus effect" was investigated, i.e. whether the 1st and 99th percentiles in the distribution of effect sizes were in opposite directions. Results Nine nalmefene and 51 naltrexone RCTs were included. No study provided a direct comparison between the drugs. We performed 9216 meta-analyses for the indirect comparison with a median of 16 RCTs (interquartile range = 12-21) included in each meta-analysis. The standardized effect size was negative at the 1st percentile (- 0.29, favouring nalmefene) and positive at the 99th percentile (0.29, favouring naltrexone). A total of 7.1% (425/5961) of the meta-analyses with a negative effect size and 18.9% (616/3255) of those with a positive effect size were statistically significant (p < 0.05). Conclusions The choice of inclusion/exclusion criteria and analytical models for meta-analysis can result in entirely opposite results. VoE evaluations could be performed when overlapping meta-analyses on the same topic yield contradictory result.
引用
收藏
页数:13
相关论文
共 108 条
[71]   Nonindependence and sensitivity analyses in ecological and evolutionary meta-analyses [J].
Noble, Daniel W. A. ;
Lagisz, Malgorzata ;
O'dea, Rose E. ;
Nakagawa, Shinichi .
MOLECULAR ECOLOGY, 2017, 26 (09) :2410-2425
[72]   Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska Natives and non-natives residing in rural settings: A randomized controlled trial [J].
O'Malley, Stephanie S. ;
Robin, Robert W. ;
Levenson, Aryeh L. ;
Wolf, Iva Grey ;
Chance, Lawrence E. ;
Hodgkinson, Colin A. ;
Romano, Denise ;
Robinson, Jane ;
Meandzija, Boris ;
Stillner, Verner ;
Wu, Ran ;
Goldman, David .
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2008, 32 (07) :1271-1283
[73]   Reduction of Alcohol Drinking in Young Adults by Naltrexone: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Efficacy and Safety [J].
O'Malley, Stephanie S. ;
Corbin, William R. ;
Leeman, Robert F. ;
DeMartini, Kelly S. ;
Fucito, Lisa M. ;
Ikomi, Jolomi ;
Romano, Denise M. ;
Wu, Ran ;
Toll, Benjamin A. ;
Sher, Kenneth J. ;
Gueorguieva, Ralitza ;
Kranzler, Henry R. .
JOURNAL OF CLINICAL PSYCHIATRY, 2015, 76 (02) :E207-+
[74]   Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation [J].
O'Malley, Stephanie S. ;
Krishnan-Sarin, Suchitra ;
McKee, Sherry A. ;
Leeman, Robert F. ;
Cooney, Ned L. ;
Meandzija, Boris ;
Wu, Ran ;
Makuch, Robert W. .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2009, 12 (05) :589-597
[75]   GOSH - a graphical display of study heterogeneity [J].
Olkin, Ingram ;
Dahabreh, Issa J. ;
Trikalinos, Thomas A. .
RESEARCH SYNTHESIS METHODS, 2012, 3 (03) :214-223
[76]  
OMALLEY SS, 1992, ARCH GEN PSYCHIAT, V49, P881
[77]   A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention [J].
Oslin, David W. ;
Lynch, Kevin G. ;
Pettinati, Helen M. ;
Kampman, Kyle M. ;
Gariti, Peter ;
Gelfand, Lois ;
Ten Have, Thomas ;
Wortman, Shoshana ;
Dundon, William ;
Dackis, Charles ;
Volpicelli, Joseph R. ;
O'Brien, Charles P. .
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2008, 32 (07) :1299-1308
[78]   Naltrexone vs Placebo for the Treatment of Alcohol Dependence A Randomized Clinical Trial [J].
Oslin, David W. ;
Leong, Shirley H. ;
Lynch, Kevin G. ;
Berrettini, Wade ;
O'Brien, Charles P. ;
Gordon, Adam J. ;
Rukstalis, Margaret .
JAMA PSYCHIATRY, 2015, 72 (05) :430-437
[79]   A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel users [J].
Osnabrugge, Ruben L. ;
Head, Stuart J. ;
Zijlstra, Felix ;
ten Berg, Jurrien M. ;
Hunink, Myriam G. ;
Kappetein, A. Pieter ;
Janssens, A. Cecile J. W. .
GENETICS IN MEDICINE, 2015, 17 (01) :3-11
[80]   Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate [J].
Palpacuer, Clement ;
Duprez, Renan ;
Huneau, Alexandre ;
Locher, Clara ;
Boussageon, Remy ;
Laviolle, Bruno ;
Naudet, Florian .
ADDICTION, 2018, 113 (02) :220-237